Evidence map›Paper›PMID 29901695›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2019

Depressive Symptoms and Engagement in Human Immunodeficiency Virus Care Following Antiretroviral Therapy Initiation.

Angela M Bengtson, Brian W Pence, Matthew J Mimiaga, Bradley N Gaynes, Richard Moore, Katerina Christopoulos, Conall O'Cleirigh, David Grelotti, Sonia Napravnik, Heidi Crane and 1 more

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Conceptualizations of Mental Health Among Young Black Gay, Bisexual, and Other Men (YB-GBMSM) Who Have Sex With Men Who Are Living With HIV.AIDS education and prevention : official publication of the International Society for AIDS Education · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Angela M BengtsonDepartment of Epidemiology, Brown University School of Public Health, Providence, Rhode Island.
Brian W PenceDepartment of Epidemiology, University of North Carolina at Chapel Hill.
Matthew J MimiagaDepartments of Behavioral & Social Health Sciences and Epidemiology, Brown University School of Public Health.
Bradley N GaynesDepartment of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, Baltimore, Maryland.
Richard MooreDepartment of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Katerina ChristopoulosHIV/AIDS Division, San Francisco General Hospital, University of California.
Conall O'CleirighDepartment of Psychiatry, Massachusetts General Hospital, Boston.
David GrelottiDepartment of Psychiatry, University of California, San Diego.
Sonia NapravnikDivision of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill.
Heidi CraneDepartment of Medicine, School of Medicine, University of Washington, Seattle.
Michael MugaveroDepartment of Medicine and UAB Center for AIDS Research, University of Alabama at Birmingham.

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Kenneth Sherr · 1988 to 2026
$104.9M
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI OLAF KUTSCH · 1988 to 2026
$84.1M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Maile Ann Young Karris · 1994 to 2026
$78.4M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Sharon L. Hillier, JONATHAN KARN · 1994 to 2026
$50.0M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
Science/Technical CoreP2CHD041020 · NICHD · BROWN UNIVERSITY · PI Margot Jackson · 2016 to 2026
$7.6M
The Causal Effect of Effective Depression Treatment on HIV Outcomes in CNICSR01MH100970 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PENCE, BRIAN W · 2013 to 2015
$1.3M
NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI036214NIAID NIH HHS P30 AI036219NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI060354NIAID NIH HHS P30 AI094189NIAID NIH HHS R24 AI067039NICHD NIH HHS P2C HD041020NIDA NIH HHS U01 DA036935NIMH NIH HHS K99 MH112413NIMH NIH HHS L30 MH110572NIMH NIH HHS R01 MH100970
6 · The paper itself

Abstract

Background: The effect of depressive symptoms on progression through the human immunodeficiency virus (HIV) treatment cascade is poorly characterized. Methods: We included participants from the Centers for AIDS Research Network of Integrated Clinic Systems cohort who were antiretroviral therapy (ART) naive, had at least 1 viral load and HIV appointment measure after ART initiation, and a depressive symptom measure within 6 months of ART initiation. Recent depressive symptoms were measured using the Patient Health Questionnaire-9 (PHQ-9) and categorized using a validated cut point (PHQ-9 ≥10). We followed participants from ART initiation through the first of the following events: loss to follow-up (>12 months with no HIV appointment), death, administrative censoring (2011-2014), or 5 years of follow-up. We used log binomial models with generalized estimating equations to estimate associations between recent depressive symptoms and having a detectable viral load (≥75 copies/mL) or missing an HIV visit over time. Results: We included 1057 HIV-infected adults who contributed 2424 person-years. At ART initiation, 30% of participants reported depressive symptoms. In multivariable analysis, recent depressive symptoms increased the risk of having a detectable viral load (risk ratio [RR], 1.28; 95% confidence interval [CI], 1.07, 1.53) over time. The association between depressive symptoms and missing an HIV visit (RR, 1.20; 95% CI, 1.05, 1.36) moved to the null after adjustment for preexisting mental health conditions (RR, 1.00; 95% CI, 0.85, 1.18). Conclusions: Recent depressive symptoms are a risk factor for unsuppressed viral load, while preexisting mental health conditions may influence HIV appointment adherence.

Indexed as

Drug MonitoringAdultAnti-Retroviral AgentsCohort StudiesDepressionFollow-Up StudiesHIV InfectionsHumansMiddle AgedViral LoadAnti-Retroviral Agents

Identifiers

PMID29901695
PMCPMC6336906

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.